pf-05175157
Small moleculeexperimental
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01274663)
Timeline
Indications
Mechanism of action
- Acetyl-CoA carboxylaseINHIBITOR
Acetyl-CoA carboxylase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1- Mol. weight
- 405.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3359265 ↗
Also known as
- pf-05175157
- pf-05175157
- pf-05175157
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02100527 | Phase 2 | Apr 1, 2014 | Pfizer |
| NCT02053116 | Phase 2 | Mar 1, 2014 | Pfizer |
| NCT02053103 | Phase 2 | Mar 1, 2014 | Pfizer |
| NCT01807377 | Phase 1 | Apr 1, 2013 | Pfizer |
| NCT01819922 | Phase 1 | Apr 1, 2013 | Pfizer |
| NCT01821079 | Phase 1 | Mar 1, 2013 | Pfizer |
| NCT01792635 | Phase 2 | Dec 1, 2012 | Pfizer |
| NCT01757756 | Phase 1 | Oct 1, 2012 | Pfizer |
| NCT01537497 | Phase 1 | Mar 1, 2012 | Pfizer |
| NCT01469468 | Phase 1 | Nov 1, 2011 | Pfizer |
| NCT01433380 | Phase 1 | Jul 1, 2011 | Pfizer |
| NCT01396161 | Phase 1 | Jul 1, 2011 | Pfizer |
| NCT01274663 | Phase 1 | Nov 1, 2010 | Pfizer |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 13 | 13 | 2 | 2010 |
1 organizations
Page 1 / 1